Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market (OTCMKTS:ELTP)

Elite Pharmaceuticals (ELTP) Q4 FY2026 earnings call: $149M revenue, $49M op income, new launches, ANDA updates, Nasdaq/M&A plans—read now.